PDF(Pubmed)
Abstract：
BACKGROUND: To analyze the economic benefits of paliperidone palmitate in the treatment of schizophrenia.
METHODS: We collected 546 patients who met the diagnostic criteria for schizophrenia according to the 《International Statistical Classification of Diseases and Related Health Problems,10th》(ICD-10). We gathered general population data such as gender, age, marital status, and education level, then initiated treatment with paliperidone palmitate. Then Follow-up evaluations were conducted at 1, 3, 6, 9, and 12 months after the start of treatment to assess clinical efficacy, adverse reactions, and injection doses. We also collected information on the economic burden before and after 12 months of treatment, as well as the number of outpatient visits and hospitalizations in the past year to analyze economic benefits.
RESULTS: The baseline patients totaled 546, with 239 still receiving treatment with paliperidone palmitate 12 months later. After 12 months of treatment, the number of outpatient visits per year increased compared to before (4 (2,10) vs. 12 (4,12), Z=-5.949, P < 0.001), while the number of hospitalizations decreased (1 (1,3) vs. 1 (1,2), Z = 5.625, P < 0.001). The inpatient costs in the direct medical expenses of patients after 12 months of treatment decreased compared to before (5000(2000,12000) vs. 3000 (1000,8050), P < 0.05), while there was no significant change in outpatient expenses and direct non-medical expenses (transportation, accommodation, meal, and family accompanying expenses, etc.) (P > 0.05); the indirect costs of patients after 12 months of treatment (lost productivity costs for patients and families, economic costs due to destructive behavior, costs of seeking non-medical assistance) decreased compared to before (300(150,600) vs. 150(100,200), P < 0.05).
CONCLUSIONS: Palmatine palmitate reduces the number of hospitalizations for patients, as well as their direct and indirect economic burdens, and has good economic benefits.
METHODS: We collected 546 patients who met the diagnostic criteria for schizophrenia according to the 《International Statistical Classification of Diseases and Related Health Problems,10th》(ICD-10). We gathered general population data such as gender, age, marital status, and education level, then initiated treatment with paliperidone palmitate. Then Follow-up evaluations were conducted at 1, 3, 6, 9, and 12 months after the start of treatment to assess clinical efficacy, adverse reactions, and injection doses. We also collected information on the economic burden before and after 12 months of treatment, as well as the number of outpatient visits and hospitalizations in the past year to analyze economic benefits.
RESULTS: The baseline patients totaled 546, with 239 still receiving treatment with paliperidone palmitate 12 months later. After 12 months of treatment, the number of outpatient visits per year increased compared to before (4 (2,10) vs. 12 (4,12), Z=-5.949, P < 0.001), while the number of hospitalizations decreased (1 (1,3) vs. 1 (1,2), Z = 5.625, P < 0.001). The inpatient costs in the direct medical expenses of patients after 12 months of treatment decreased compared to before (5000(2000,12000) vs. 3000 (1000,8050), P < 0.05), while there was no significant change in outpatient expenses and direct non-medical expenses (transportation, accommodation, meal, and family accompanying expenses, etc.) (P > 0.05); the indirect costs of patients after 12 months of treatment (lost productivity costs for patients and families, economic costs due to destructive behavior, costs of seeking non-medical assistance) decreased compared to before (300(150,600) vs. 150(100,200), P < 0.05).
CONCLUSIONS: Palmatine palmitate reduces the number of hospitalizations for patients, as well as their direct and indirect economic burdens, and has good economic benefits.
摘要：
背景：分析棕榈酸帕潘立酮治疗精神分裂症的经济效益。
方法：我们根据《疾病和相关健康问题国际统计分类》收集了546例符合精神分裂症诊断标准的患者，《第10号》(ICD-10)。我们收集了一般人口数据，如性别，年龄,婚姻状况,和教育水平，然后开始用棕榈酸帕潘立酮治疗。然后在治疗开始后1、3、6、9和12个月进行随访评估，以评估临床疗效。不良反应,和注射剂量。我们还收集了12个月治疗前后的经济负担信息,以及过去一年的门诊次数和住院次数，以分析经济效益。
结果：基线患者总计546例，其中239例在12个月后仍在接受帕潘立酮棕榈酸酯治疗。经过12个月的治疗，与以前相比，每年的门诊量增加(4(2,10)vs.12(4,12),Z=-5.949,P<0.001),而住院人数减少(1(1,3)vs.1(1,2),Z=5.625,P<0.001)。治疗12个月后患者的直接医疗费用中的住院费用与以前相比有所下降(5000(2000,12000)vs.3000(1000,8050),P<0.05),而门诊费用和直接非医疗费用没有显著变化(交通，住宿,膳食,和家庭陪同费用，等。）（P>0.05）；治疗12个月后患者的间接成本（患者和家庭的生产力损失成本，由于破坏性行为造成的经济成本，寻求非医疗援助的成本)与以前相比有所下降(300(150,600)与150(100,200),P<0.05)。
结论：棕榈酸酯减少了患者的住院次数，以及他们的直接和间接经济负担，具有良好的经济效益。
方法：我们根据《疾病和相关健康问题国际统计分类》收集了546例符合精神分裂症诊断标准的患者，《第10号》(ICD-10)。我们收集了一般人口数据，如性别，年龄,婚姻状况,和教育水平，然后开始用棕榈酸帕潘立酮治疗。然后在治疗开始后1、3、6、9和12个月进行随访评估，以评估临床疗效。不良反应,和注射剂量。我们还收集了12个月治疗前后的经济负担信息,以及过去一年的门诊次数和住院次数，以分析经济效益。
结果：基线患者总计546例，其中239例在12个月后仍在接受帕潘立酮棕榈酸酯治疗。经过12个月的治疗，与以前相比，每年的门诊量增加(4(2,10)vs.12(4,12),Z=-5.949,P<0.001),而住院人数减少(1(1,3)vs.1(1,2),Z=5.625,P<0.001)。治疗12个月后患者的直接医疗费用中的住院费用与以前相比有所下降(5000(2000,12000)vs.3000(1000,8050),P<0.05),而门诊费用和直接非医疗费用没有显著变化(交通，住宿,膳食,和家庭陪同费用，等。）（P>0.05）；治疗12个月后患者的间接成本（患者和家庭的生产力损失成本，由于破坏性行为造成的经济成本，寻求非医疗援助的成本)与以前相比有所下降(300(150,600)与150(100,200),P<0.05)。
结论：棕榈酸酯减少了患者的住院次数，以及他们的直接和间接经济负担，具有良好的经济效益。
